Most Read Articles
16 Jan 2021
Diagnosis of heart diseases has abruptly and significantly decreased across the globe due to the coronavirus disease 2019 (COVID-19) pandemic, especially affecting poorer countries, reveals a study.
Roshini Claire Anthony, 01 Dec 2020

An evidence-based, multifaceted intervention aimed at reducing haemodialysis catheter-related bloodstream infections (HD-CRBSIs) failed to improve this outcome, results of the REDUCCTION* trial showed.

Pearl Toh, 2 days ago
While it is well known that COVID-19 illness is associated with coagulopathy, the optimal anticoagulation strategy remains elusive, and two studies presented at the ASH 2020 Congress further add to the growing debate on the appropriate anticoagulant dose for hospitalized patients with COVID-19.

Bone mass higher in HIV+ children on efavirenz than lopinavir/ritonavir

Audrey Abella
13 Apr 2020

Children with HIV (HIV+) who switched to efavirenz had higher bone mass even after 4 years of switching compared with those who remained on an antiretroviral therapy (ART) regimen comprising lopinavir and ritonavir, according to data presented at CROI 2020.

“This analysis presents 2 additional years of follow up [and supports our] previous report [showing that] South African [HIV+] children [who] remained on a lopinavir/ritonavir-based ART … had lower bone mass compared with HIV+ children who switched to efavirenz and children [without HIV (HIV-)],” said the researchers. [AIDS 2016;30:2459-2467]

The CHANGES Bone Study enrolled 440 children (mean age at baseline 6.7 years, 51.8 percent male) from Johannesburg, South Africa. Of these, 202 were HIV+ who either switched to efavirenz (n=107) or remained on lopinavir/ritonavir (n=95), while 202 were HIV-. Total body bone mineral content (TB-BMC) was evaluated using dual-energy X-ray absorptiometry. TB-BMC Z-scores were adjusted for age, sex, height, and race. [CROI 2020, abstract 821]

Over the 2-year follow up period, TB BMC Z-scores dropped at a rate of -0.12, -0.13 and -0.11 per year for HIV+ children on efavirenz, HIV+ children on lopinavir/ritonavir, and HIV- subjects, respectively.

TB BMC Z-scores were significantly higher among HIV+ children on efavirenz compared with those on lopinavir/ritonavir at baseline (-0.77 vs -1.14), at 1 year (-0.94 vs -1.34), and at 2 years (-1.01 vs -1.40; p<0.01 for all).

Compared with HIV- children, HIV+ children who switched to efavirenz had similar TB BMC Z-scores across all timepoints (-0.77 vs -0.82; p=0.54 [baseline], -0.94 vs -0.95; p=0.95 [1 year], -1.01 vs -1.04; p=0.71 [2 years]).

Despite early initiation of a potent ART regimen among virally suppressed South African HIV+ children, bone mass, formation, and resorption remain lower compared with HIV- children, noted the researchers. [Arch Osteoporos 2018;13:40] The consistent bone accrual benefit achieved with efavirenz underscores its potential in improving these bone conditions in this patient setting, noted the researchers.

“Although these findings reflected a slight overall decline in bone mass among HIV+ children compared with US population norms, [our] findings support our previous recommendations to switch children with sustained viral suppression on first-line regimen with lopinavir/ritonavir to efavirenz,” they concluded.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
16 Jan 2021
Diagnosis of heart diseases has abruptly and significantly decreased across the globe due to the coronavirus disease 2019 (COVID-19) pandemic, especially affecting poorer countries, reveals a study.
Roshini Claire Anthony, 01 Dec 2020

An evidence-based, multifaceted intervention aimed at reducing haemodialysis catheter-related bloodstream infections (HD-CRBSIs) failed to improve this outcome, results of the REDUCCTION* trial showed.

Pearl Toh, 2 days ago
While it is well known that COVID-19 illness is associated with coagulopathy, the optimal anticoagulation strategy remains elusive, and two studies presented at the ASH 2020 Congress further add to the growing debate on the appropriate anticoagulant dose for hospitalized patients with COVID-19.